Ortho Immun

Ortho Immun Receives FDA Approval for New Drug to Treat Chronic Kidney Disease

Ortho Immun, a leading pharmaceutical company, has announced that it has received approval from the U.S. Food and Drug Administration (FDA) for a new drug to treat chronic kidney disease (CKD). The drug, called Kerendia, is the first new medication approved for CKD in over a decade.

CKD is a serious condition that affects millions of Americans. It is a progressive disease that can lead to kidney failure and other serious health problems. Kerendia is a once-daily pill that is taken orally. It is designed to help slow the progression of CKD and reduce the risk of kidney failure.

Kerendia was approved based on the results of a Phase 3 clinical trial that involved over 4,000 patients. The trial found that Kerendia was effective in slowing the progression of CKD and reducing the risk of kidney failure. The drug was also well-tolerated by patients.

The approval of Kerendia is a major breakthrough in the treatment of CKD. It is the first new drug approved for CKD in over a decade, and it offers new hope to patients who are living with this condition.